Early TPT Strategy Is Becoming a Defining Advantage for MedTech Innovators

Why some technologies succeed and others fail

Voyageur
Market Access

TPT as a Strategic Differentiator

In the race to bring new medical technologies to market, the conversation often centers on regulatory milestones, clinical evidence, and commercial readiness. But in 2026, one theme is rising above the noise: Transitional Pass-Through (TPT) payment strategy is now a critical early-stage differentiator for companies seeking to accelerate adoption and secure investor confidence. The latest OPPS Final Rule makes this clearer than ever. The Centers for Medicare & Medicaid Services (CMS) continues to reward companies that treat TPT not as a reimbursement afterthought, but as a strategic pillar woven into product design, evidence development, and commercialization planning. For executives and investors, the implications are profound.

TPT is no longer simply a payment mechanism. It’s a catalyst for early revenue, a signal of clinical differentiation, and a powerful tool for reducing friction in hospital adoption. And for venture and private equity partners, it’s becoming a leading indicator of whether a technology is positioned for scalable success. Against this backdrop, innovators that operationalize TPT in the earliest phases of product development—well before FDA clearance—are building structural advantages that compound over time. That advantage shows up in faster hospital onboarding, cleaner coding and billing pathways, stronger sales enablement, and a clearer investment story. Today's environment demands that leadership teams elevate TPT to the same level of rigor as design controls, clinical strategy, and market access planning.


Policy

The New Reality: CMS Is Raising the Bar

The 2026 Final Rule reinforces a pattern that has been building for several years: CMS is applying sharper scrutiny to TPT applications, especially around integrality, non-substitutability, and evidence quality. At the same time, the agency is rewarding companies that demonstrate clarity, transparency, and early planning. Three themes stand out and now define what “good” looks like for TPT.

- Integrality must be engineered, not argued.
- Breakthrough Device Designation is becoming a strategic accelerant.
- Cost transparency is non-negotiable.

Integrality must be engineered, not argued. CMS wants to see that every component of a device system is essential to the procedure and cannot be replaced with off-the-shelf alternatives. Companies that treat this as a documentation exercise are falling behind. The winners are those who design integrality into the product from the start. Breakthrough Device Designation is becoming a strategic accelerant. For eligible technologies, Breakthrough status removes the need to prove substantial clinical improvement at the time of application. This pathway is increasingly shaping early-stage regulatory and evidence strategy—and investors are taking notice. Cost transparency is non-negotiable. CMS expects clear, defensible cost data aligned with APC-level payment structures. Companies that cannot articulate their cost position with precision are struggling to gain traction.

Why Some TPT Applications Fail — And What We Learn From Them

While successful applicants share a common playbook, companies that fall short tend to make predictable mistakes. These failures offer valuable lessons for innovators and investors planning early-stage strategies. The patterns are not mysterious: they are rooted in avoidable ambiguity, late planning, or evidence that does not withstand CMS scrutiny. By surfacing these issues early, teams can de-risk timelines and strengthen both payer and provider confidence.

Unclear or Weak Demonstration of Integrality

- All components are essential to the procedure
- Instruments or screws are proprietary
- Parts of the “kit” resemble supplies rather than integral device components

Lesson: Integrality must be proven with engineering documentation, FDA labeling, and clear explanations of why no alternative components can be used. If CMS sees ambiguity, the application is at risk. The strongest dossiers show how the system functions only when all components work together, supported by design files, instructions for use, and risk analysis that makes substitution unsafe or infeasible.

Insufficient Clinical Evidence or Overreliance on Theoretical Benefits

- Peer-reviewed data
- Real-world outcomes
- Comparative effectiveness

Applications often fail when companies rely on: - Hypothetical benefits - Workflow improvements - Convenience claims - Small or non-generalizable studies.

Lesson: Evidence planning must begin early. Companies should build a clinical strategy that supports both TPT and long-term coverage—not scramble for data after FDA clearance. The most credible submissions triangulate RCT or robust prospective data with pragmatic registries and site-reported outcomes.

Ambiguous Device Configurations or Multiple Variants

- It’s unclear whether multiple configurations represent one system or several
- Indications differ across variants
- Components vary in ways that affect integrality or cost

Lesson: Clarity is everything. Companies must define the system architecture, explain variant differences, and justify why configurations should be evaluated together. A clean mapping from configuration to indication and component cost helps CMS evaluate non-substitutability without guesswork.


3°
3°

Weak or Incomplete Cost Methodology

- Missing acquisition cost documentation
- Inconsistent methodology
- Failure to meet the non-insignificant cost thresholds
- Lack of transparency in how costs were calculated

Lesson: Cost modeling must be built with the same rigor as clinical evidence. CMS expects clear, defensible, APC-aligned data. This includes supplier invoices, bill of material detail, allocation assumptions for capital versus disposable elements, and sensitivity analyses that demonstrate threshold compliance under reasonable variability. Teams that pre-align on cost narratives avoid rework and delays.

Reactive Engagement With CMS

Some companies wait until the application is submitted—or worse, until CMS raises concerns—to clarify key issues. This reactive posture often leads to misalignment, misinterpretation, and missed opportunities to strengthen the application.

Lesson: Early engagement with CMS is essential. Pre-submission meetings and proactive communication can prevent avoidable pitfalls. The intent is not to lobby, but to create shared clarity on system boundaries, evidence maturity, and coding implications.

Failure to Articulate Beneficiary Access Impact

CMS is increasingly focused on access barriers, equity considerations, and patient-specific benefits. Applications that fail to articulate how TPT improves access often lose momentum.

Lesson: The beneficiary access narrative must be explicit, evidence-based, and integrated into the application—not treated as an afterthought. Link clinical endpoints to functional outcomes, geography, and site-of-service realities to demonstrate why TPT accelerates equitable access for Medicare beneficiaries.

Seven Moves That Separate the Winners

Winning teams operationalize TPT across design, clinical, and commercial tracks. They treat each TPT requirement as a design constraint and as a storytelling opportunity with investors and providers.

1. They treat TPT as a strategic milestone—not a regulatory task.

TPT planning is built into product roadmaps, fundraising narratives, and launch sequencing. It's part of the business strategy, not a box to check.

2. They pursue Breakthrough Device Designation early.

This is one of the highest-ROI regulatory steps available for eligible technologies. It accelerates timelines, strengthens investor confidence, and simplifies the TPT pathway.

3. They engineer integrality into the product.

From proprietary instruments to inseparable components, successful companies design their systems so CMS can clearly see that every part is essential.

4. They build evidence with intention.

Even with Breakthrough designation, CMS responds strongly to peer-reviewed data, real-world outcomes, and comparative effectiveness. Evidence planning starts early and aligns with both TPT and long-term coverage goals.

5. They prepare cost data with the same rigor as clinical data.

Transparent acquisition cost, clear methodology, and alignment with APC payment structures are now table stakes.

6. They engage CMS early and often.

Pre-submission meetings, clarification discussions, and proactive communication help avoid surprises and strengthen applications.

7. They make beneficiary access central to their narrative.

CMS is responsive to arguments grounded in patient access, equity, and clinical need. Companies that articulate these themes clearly are more likely to succeed.


Voyageur
Market Access

The Bottom Line

The 2026 OPPS Final Rule underscores a simple truth: TPT success is predictable for companies that plan early, integrate evidence and engineering, and treat reimbursement as a strategic advantage.

For innovators, this means embedding TPT into early product and clinical strategy.

For investors, it means evaluating TPT readiness as a marker of commercial maturity and risk mitigation.

For the industry as a whole, it signals a shift toward more disciplined, evidence-driven innovation. The companies that win in this environment are not just building great technologies—they're building great strategies.



www.voyageurmarketaccess.com

Voyageur

Market Access